BofA lowered the firm’s price target on Braskem (BAK) to $3.30 from $3.70 and keeps a Neutral rating on the shares after the Brazilian President sanctioned the Draft Bill (PL) 892/2025, which establishes the PRESIQ benefit and the REIQ’s rate schedule, but vetoed the proposed increase in REIQ for 2026. The firm had already incorporated the benefits of the increase in REIQ for 2026 and the Presiq for 2027-31, so it therefore sees the news as negative, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAK:
- Braskem Highlights New Brazilian Incentive Program PRESIQ and Continuity of REIQ Regime
- Braskem Locks In Long-Term Petrobras Feedstock Deals to Support Brazil Petrochemical Operations and Expansion
- IG4 Capital seals agreement to assume Novonor’s Braskem stake
- Braskem S.A. Announces Potential Ownership Changes Following Novonor Agreement
- Braskem S.A. Unveils 2026 Corporate Event Calendar